Advanced search
Publication Cover
Clinical Pharmacology: Advances and Applications Volume 13, 2021 - Issue
Submit an article Journal homepage
178
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Population Pharmacokinetics of CC-122

Yiming Cheng1 Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, NJ, USAView further author information
,
Jian Chen2 Non-Clinical Research & Development, Bristol Myers Squibb, Summit, NJ, USAView further author information
,
Michael Pourdehnad3 Early Clinical Development, Bristol Myers Squibb, San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0001-8701-930XView further author information
ORCID Icon,
Simon Zhou1 Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, NJ, USAView further author information
&
Yan Li1 Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, NJ, USACorrespondence[email protected]
View further author information
Pages 61-71 | Published online: 28 Apr 2021

References

  • Cubillos-Zapata C, Cordoba R, Avendaño-Ortiz J, et al. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma. Oncoimmunology. 2016;5(12):e1231290. doi:10.1080/2162402X.2016.123129028255524
  • Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. A novel drug, CC-122, inhibits tumor growth in hepatocellular carcinoma through downregulation of an oncogenic TCF-4 isoform. Transl Oncol. 2019;12(10):1345–1356. doi:10.1016/j.tranon.2019.07.00231352197
  • Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.26654227
  • Rasco DW, Papadopoulos KP, Pourdehnad M, et al. A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies. Clin Cancer Res. 2019;25(1):90–98. doi:10.1158/1078-0432.CCR-18-120330201761
  • Hatake K, Chou T, Doi T, et al. Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. Cancer Sci. 2021;112(1):331–338. doi:10.1111/cas.1470433075165
  • Michot JM, Bouabdallah R, Vitolo U, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol. 2020;7(9):e649–e659. doi:10.1016/S2352-3026(20)30208-832758434
  • Li Y, Carayannopoulos LN, Thomas M, Palmisano M, Zhou S. Exposure-response analysis to assess the concentration-QTc relationship of CC-122. Clin Pharmacol. 2016;8:117–125. doi:10.2147/CPAA.S11186727672344
  • Ogasawara K, MacGorman K, Liu L, et al. Drug-Drug Interaction Study to assess the effect of cytochrome P450 inhibition and induction on the pharmacokinetics of the novel cereblon modulator avadomide (CC-122) in healthy adult subjects. J Clin Pharmacol. 2019;59(12):1620–1631. doi:10.1002/jcph.145331172535
  • Li Y, MacGorman K, Liu L, et al. Single-dose pharmacokinetics, safety, and tolerability of avadomide (CC-122) in subjects with mild, moderate, or severe renal impairment. Clin Pharmacol Drug Dev. 2020;9(7):785–796. doi:10.1002/cpdd.76031891240
  • Li Y, Xu Y, Liu L, Wang X, Palmisano M, Zhou S. Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015;55(5):563–572. doi:10.1002/jcph.45525556560
  • Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22(8):1485–1493. doi:10.1038/leu.2008.13118528426
  • Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005;16(1):151–161. doi:10.1681/ASN.200410084315574506
  • Zhou J, Wen Q, Li SF, et al. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget. 2016;7(31):50612–50623. doi:10.18632/oncotarget.943727203676
  • Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther. 2008;83(6):894–897. doi:10.1038/clpt.2008.5518388870
  • Yan T, Lu L, Xie C, et al. Severely impaired and dysregulated cytochrome P450 expression and activities in hepatocellular carcinoma: implications for personalized treatment in patients. Mol Cancer Ther. 2015;14(12):2874–2886. doi:10.1158/1535-7163.MCT-15-027426516155
  • Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemother Pharmacol. 2018;81(6):1071–1082. doi:10.1007/s00280-018-3581-029687244
  • Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol. 2019;84(4):891–898. doi:10.1007/s00280-019-03929-931444617
  • Farkouh A, Riedl T, Gottardi R, Czejka M, Kautzky-Willer A. Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature. Adv Ther. 2020;37(2):644–655. doi:10.1007/s12325-019-01201-331873866
  • Kekki M, Samloff IM, Ihamäki T, Varis K, Siurala M. Age- and sex-related behaviour of gastric acid secretion at the population level. Scand J Gastroenterol. 1982;17(6):737–743. doi:10.3109/003655282091810877188552

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.